CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
56.51
0%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-4.61)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.39)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 56.51
Open 56
1-Year Change 8.74%
Day's Range 55.61 - 56.53
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 13, 2024 56.51 0.34 0.61% 56.17 56.56 55.61
Dec 12, 2024 56.51 -0.55 -0.96% 57.06 59.44 56.42
Dec 11, 2024 59.09 -0.59 -0.99% 59.68 60.26 58.24
Dec 10, 2024 59.05 1.66 2.89% 57.39 59.16 57.03
Dec 9, 2024 57.96 1.74 3.09% 56.22 58.64 56.00
Dec 6, 2024 56.91 0.91 1.62% 56.00 57.28 55.59
Dec 5, 2024 55.79 -0.67 -1.19% 56.46 56.64 55.59
Dec 4, 2024 56.67 1.39 2.51% 55.28 57.61 55.28
Dec 3, 2024 56.72 -0.33 -0.58% 57.05 57.47 56.06
Dec 2, 2024 57.73 1.04 1.83% 56.69 58.37 56.15
Nov 29, 2024 56.96 -0.99 -1.71% 57.95 58.57 56.58
Nov 27, 2024 59.29 2.11 3.69% 57.18 59.39 57.01
Nov 26, 2024 57.82 -0.22 -0.38% 58.04 58.65 56.43
Nov 25, 2024 58.50 1.86 3.28% 56.64 59.00 56.45
Nov 22, 2024 56.82 1.87 3.40% 54.95 57.06 54.95
Nov 21, 2024 55.77 0.72 1.31% 55.05 56.24 54.34
Nov 20, 2024 55.02 0.65 1.20% 54.37 56.11 54.37
Nov 19, 2024 55.48 1.08 1.99% 54.40 55.83 53.81
Nov 18, 2024 55.20 -1.35 -2.39% 56.55 56.55 54.74
Nov 15, 2024 56.40 -2.33 -3.97% 58.73 58.76 55.89

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

ANI Pharma Company profile

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. It operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, ANI Pharmaceuticals Inc revenues increased 4% to $216.1M. Net loss applicable to common stockholders increased 90% to $42.8M. Revenues reflect Royalties from licensing agreements segment increase from $1.4M to $11.8M, Other segment increase from $783K to $1.9M, United States segment increase of 4% to $211.9M. Higher net loss reflects Selling.

Equity composition

6Common Stock $.0001 Par, 3/10, unlim. auth., 93,590,612 issd. Insiders own 2.43%. IPO: N/A. Cl. C Common no Par, 12/10, unlim. auth., 391,286 issd. 5/31/02 1-for-10 reverse stock split. *7/06, private placement of 3,812,978 shares @ 04/06, 1-for-6 Reverese stock split. 07/13, 1-for-6 Reverese stock split.

Industry: Pharmaceuticals (NEC)

210 Main Street West
BAUDETTE
MINNESOTA 56623
US

People also watch

XRP/USD

2.40 Price
-1.870% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01196

ETH/USD

3,845.24 Price
-1.620% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,648.80 Price
-1.210% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee 0.0043%
Overnight fee time 22:00 (UTC)
Spread 0.60

US100

21,741.60 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0020%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading